摘要
《新型冠状病毒肺炎诊疗方案(试行第七版)》延续第六版,推荐5种抗新型冠状病毒(SARS-CoV-2)的药物,同时强调药物毒性反应、相互作用的警示,关注特殊患者群抗病毒药物的选择。肿瘤患者是具有高感染率、高死亡率的特殊患者群,选择抗病毒药物应慎重,以期获得高效低毒的治疗效果。本文根据小分子口服肿瘤靶向药物的临床应用与毒性特点,结合肿瘤患者病理、生理特征,参考抗病毒药物临床及基础研究的相关文献数据,对长期口服靶向药物肿瘤患者的抗病毒药物选择进行了分析与探讨。以期为临床肿瘤患者抗病毒药物的选择提供参考。
Diagnosis and Treatment Protocol for COVID-19(Trial Version 7)continues the recommendation of five antiviral drugs in the version 6.The version 7 focuses on the toxicity and interaction of the antiviral drugs,and the selection of antiviral drugs for special patient groups.Tumor patients who are special ones with high infection rate and high mortality rate should carefully choose antiviral drugs in order to obtain high-efficientness and low-toxicity treatment effect.In this paper,according to the clinical application and toxicity characteristics of small-molecule oral targeted drugs,combined with the pathological and physiological characteristics of tumor patients,and with reference to the relevant literature data of the clinical and basic research of antiviral drugs,the selection of antiviral drugs for tumor patients treated with long-term oral targeted drugs was analyzed in order to provide reference for the selection of anti-novel coronavirus drugs in clinical practice.
作者
杨珺
周海燕
朱志翔
李国辉
Yang Jun;Zhou Haiyan;Zhu Zhixiang;Li Guohui(Department of Pharmacy,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《中国药师》
CAS
2020年第9期1764-1768,共5页
China Pharmacist
基金
中国医学科学院医学与健康科技创新工程项目(编号:2016-I2M-1-001、2017-I2M-2-003)。
